James Ford, MD
Interventional Cardiology · Paducah, KYNPI 1285665182
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $55,110 of the $67,490 with a category attached, or 81.7%. Lantheus Medical Imaging, Inc. accounts for 83.4% of it on its own, with 26 other manufacturers making up the rest. Reporting peaked in 2022 at $17,675 and has fallen 99.9% since, to $17 in 2025.
Across 260 payments — averaging $259.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lantheus Medical Imaging, Inc.$56K
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$5K
- Siemens Medical Solutions USA, Inc.$2K
- Abiomed$826
- Novartis$654
- Amgen$491
- plus $3K from 21 others
Across 20 payments — averaging $7988.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Lantheus Medical Imaging, Inc.$133K
- Bayer$27K
What the payments were for
- Speaking & faculty fees$55,11082%
- Travel & lodging$5,5078%
- Food & beverage$6,87310%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lantheus Medical Imaging, Inc. | 77 | $56,255 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 10 | $4,755 |
| Siemens Medical Solutions USA, Inc. | 3 | $1,736 |
| Abiomed | 10 | $826 |
| Novartis | 46 | $654 |
| Amgen | 19 | $491 |
| Abbott | 7 | $475 |
| Medtronic | 5 | $425 |
| Inari Medical, Inc. | 3 | $355 |
| Boston Scientific | 7 | $268 |
| Johnson & Johnson | 17 | $204 |
| Shockwave Medical, Inc | 7 | $179 |
| Pfizer | 12 | $161 |
| Boehringer Ingelheim | 8 | $125 |
| E.r. Squibb & Sons, L.L.C. | 7 | $96 |
| Actelion Pharmaceuticals US, Inc. | 1 | $92 |
| Cvrx, Inc. | 1 | $88 |
| Sanofi-aventis U.S. LLC | 5 | $82 |
| Elutia, Inc. | 4 | $60 |
| Astellas Pharma US Inc | 2 | $37 |
| Irhythm Technologies, Inc. | 2 | $33 |
| Aegerion Pharmaceuticals, Inc. | 2 | $26 |
| Philips North America LLC | 1 | $16 |
| Penumbra, Inc. | 1 | $15 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $14 |
| Arbor Pharmaceuticals, Inc. | 1 | $12 |
| AstraZeneca | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Definity$54,507
- LifeVest$4,600
- ACUSON SC2000 Diagnostic Ultrasound System$1,710
- Impella$391
- FLOWTRIEVER CATHETER, S$318
- CT THROMBECTOMY SYSTEM KIT$318
- MitraClip$163
- Micra$134
- AZURE XT DR MRI SURESCAN$113
- QUADRA ASSURA$112
- Repatha$110
- Watchman$105
How this compares
$67,490 in reported general payments places this provider in the 85th percentile of 129 interventional cardiology providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 58 | $49,345 |
| XareltoRivaroxaban | 31 | $32,707 |
| EntrestoSacubitril/Valsartan | 17 | $25,527 |
| Repatha SureclickEvolocumab | 21 | $13,698 |
| BrilintaTicagrelor | 22 | $13,688 |
| Praluent PenAlirocumab | 12 | $9,688 |
| Prasugrel Hcl | 33 | $3,706 |
| Atorvastatin Calcium | 88 | $594 |
| Metoprolol Succinate | 42 | $557 |
| Rosuvastatin Calcium | 58 | $556 |
| Ezetimibe | 17 | $495 |
| ClopidogrelClopidogrel Bisulfate | 43 | $322 |
| Losartan Potassium | 30 | $291 |
| Nitroglycerin | 12 | $220 |
| Warfarin Sodium | 21 | $211 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $161 | $49,34558 claims |
| Johnson & JohnsonXarelto | $204 | $32,70731 claims |
| NovartisEntresto | $654 | $25,52717 claims |
| AstraZenecaBrilinta | $12 | $13,68822 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 129 interventional cardiology providers in Kentucky.
Other interventional cardiology in Paducah
- Shankho GanguliPaducah$56K
- Martin RainsPaducah$45K
- Timothy McDermottPaducah$17K
- Michael FaulknerPaducah$13K
- Amit SrivastavaEdgewood$642K
- Avichai EresLexington$616K
- Steve LinLexington$362K
- Daniel StewartLouisville$290K
- Robert SawyerLexington$249K
- Ganesh Keshav ThirunavukkarasuLexington$220K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.